LYZ905 F
Lysander-Patient Capital Equity Fund
(formerly Lysander-18 Asset Management
Canadian Equity Fund)
Series F


  • Asset Class
  • Category
    Global Equity
  • Risk Rating
  • Number of Securities


  • CAD $ NAV
  • Change NAV $
  • Change NAV %
  • Date


The Fund’s objective is to provide long-term capital growth by investing primarily in equity securities anywhere in the world.

Investment Focus

Invests in the equity securities of global companies with an Absolute Value focus.

Fund Facts

December 31, 2021
Inception Date December 30, 2014
Currency CAD
Fund AUM $5.6 Million
NAVPU $12.07
Management Fee 0.80%
MER as of June 30, 2021 (unaudited) 1.00%
Minimum Initial Investment $1,000
Minimum Subsequent Investment $100
Liquidity Daily
RRSP Eligible Yes

Portfolio Characteristics

Number of Securities 13
Dividend Yield 1.6%

The NAVs posted are post-distribution.

Top 10 Holdings

December 31, 2021
Security % of fund
Canadian Dollar 61.9%
Bank of Nova Scotia 4.8%
Canadian Natural Resources 4.4%
Honda Motor Co. Ltd. ADR 4.4%
Cdn. Utilities Ltd. 4.1%
Toronto Dominion Bank 3.5%
Bank of Montreal 3.4%
Royal Bank of Canada 3.3%
Canadian Imperial Bank of Commerce 3.2%
Verizon Communications Inc. 2.8%
Total 95.8%

Geographic Breakdown

Inception Date

December 30, 2014

As of Date

December 31, 2021

Compound Returns

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Year
  • 5 Year
  • Since Inception

Calendar Year Returns


Distribution Frequency: Quarterly
Most Recent Distribution per Unit: $3.5087
12-Month Trailing Distribution Yield: 30.6%
Next Record Date: March 24, 2022
Next Distribution Date: March 25, 2022

Quarterly Distributions

Record Date Distribution Date
March 24, 2022 March 25, 2022
June 23, 2022 June 24, 2022
September 29, 2022 September 30, 2022
December 29, 2022 December 30, 2022
Distributions ($)/Unit2 YTD* 2020 2019 2018 2017 2016 2015
Total Distributions 3.6920 0.2820 0.8276 0.1962 0.1581 0.1829 0.1186
Interest 0.0000
Dividends 0.2820 0.2308 0.1643 0.1581 0.1829 0.1186
Capital Gains 0.0000 0.5968 0.0319
Withholding Tax 0.0000

*The final tax character will be determined based on the Fund’s tax year end information

Lysander Funds Limited is the investment fund manager of Lysander Patient Capital Equity Fund (the “Fund”). This
document is not an invitation to invest in the Fund and does not constitute a public offering of sale. Purchases in the Fund can only be
made through an Investment Professional on the terms in the Fund’s offering document by eligible investors. Each purchaser of units in a
fund may have statutory or contractual right of action. Commissions, trailing commissions, management fees and expenses all may be
associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are historical annual
compounded total returns including changes in unit value and reinvestment of all distributions and do not take into account sales,
redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual
funds are not guaranteed or insured, their values change frequently and past performance may not be repeated. 1Source: TSX © Copyright
2021 TSX Inc. All Rights Reserved. 2Distributions are based on the actual number of units outstanding at the relevant time. Distributions are
paid in cash or reinvested in additional units. If the series’ net income/capital gains is less than the amounts distributed in the year,
the distribution will include a return of capital. In these circumstances, if an investor elects to receive their distributions in cash and not
reinvest distributions, it is expected that the value of their investment will decline over time. Distributions are not an indication of
performance, rate of return or yield. On November 1, 2021, the portfolio manager of the fund changed from 18 Asset Management Inc. to Patient Capital Management Inc. and the investment objective of the fund no longer had a Canadian equity securities focus. These changes could have affected the performance of the fund had these changes been in effect throughout the performance measurement period. ®Lysander Funds is a registered trademark of Lysander Funds Limited.

Your Cookie Settings

We have updated our Privacy Policy effective October 2021. We encourage you to review it carefully.

We use cookies to improve your experience. By continuing to use this website, or other online services, you agree to the use of cookies and consent to the practices described in our Privacy Policy and Terms of Use.